رجوع
نطاق اليوم
KWD 61.98
KWD 63.68
نطاق 52 أسبوعًا
KWD 32.48
KWD 71.92
حجم التداول
647,884
متوسط 50 يوم / 200 يوم
KWD 64.85
/
KWD 55.98
الإغلاق السابق
KWD 63.24
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Healthcare (627 نظير)
| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -14.1 | 0.3 |
| P/B | 2.8 | 2.9 |
| ROE % | -19.2 | 3.7 |
| Net Margin % | -17.5 | 3.8 |
| Rev Growth 5Y % | 7.6 | 10.0 |
| D/E | 0.4 | 0.2 |
السعر المستهدف للمحللين
Hold
KWD 75.880
+21.6%
Low: KWD 66.000
High: KWD 85.000
مكرر الربحية المستقبلي
15.0
ربحية السهم المستقبلية
KWD 4.209
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
1.5 B
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2030 |
KWD 6.410
KWD 6.142 – KWD 6.533
|
1.9 B | 1 |
| FY2029 |
KWD 5.810
KWD 5.567 – KWD 5.921
|
1.8 B | 1 |
| FY2028 |
KWD 5.049
KWD 4.596 – KWD 5.503
|
1.7 B | 2 |
Insider Trading Activity
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 11, 2026 |
Poletti Franco
President, Cardiopulmonary
|
other | 6,329 | KWD 57.600 | — |
| Dec 15, 2025 |
Poletti Franco
President, Cardiopulmonary
|
other | 2,350 | — | — |
| Dec 15, 2025 |
Hutchinson Michael Damon
SVP, CLO and Company Secretary
|
other | 5,630 | — | — |
| Dec 15, 2025 |
PODLOGAR SUSAN M
Director
|
other | 4,979 | — | — |
| Nov 18, 2025 |
Story Brooke
Director
|
sell | 250 | KWD 53.940 | KWD 13,485 |
| Sep 15, 2025 |
Poletti Franco
President, Cardiopulmonary
|
other | 1,563 | — | — |
| Aug 25, 2025 |
Bianchi Francesco
Director
|
sell | 1,500 | KWD 56.500 | KWD 84,750 |
| Jun 15, 2025 |
Story Brooke
Director
|
other | 7,242 | — | — |
| Jun 15, 2025 |
Story Brooke
Director
|
grant | 4,042 | — | — |
| Jun 15, 2025 |
SCHERMERHORN TODD C
Director
|
other | 7,242 | — | — |
| Jun 15, 2025 |
SCHERMERHORN TODD C
Director
|
grant | 4,042 | — | — |
| Jun 15, 2025 |
KOZY WILLIAM A
Director
|
other | 10,261 | — | — |
| Jun 15, 2025 |
KOZY WILLIAM A
Director
|
grant | 5,681 | — | — |
| Jun 15, 2025 |
PODLOGAR SUSAN M
Director
|
grant | 4,042 | — | — |
| Jun 15, 2025 |
Barry James Christopher
Director
|
other | 7,242 | — | — |
| Jun 15, 2025 |
Barry James Christopher
Director
|
grant | 4,042 | — | — |
| Jun 15, 2025 |
Enxing Seng Stacy
Director
|
other | 7,242 | — | — |
| Jun 15, 2025 |
Enxing Seng Stacy
Director
|
grant | 4,042 | — | — |
| Jun 15, 2025 |
Tezel Ahmet
Chief Innovation Officer
|
other | 6,966 | — | — |
| Jun 15, 2025 |
WILVER PETER M
Director
|
other | 7,242 | — | — |
النقاط الرئيسية
Revenue grew 7.60% annually over 5 years — modest growth
Earnings declined -483.50% over the past year
Debt/Equity of 0.39 — conservative balance sheet
Generating 173.20M in free cash flow
PEG of 0.03 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 3.14%
النمو
Revenue Growth (5Y)
7.60%
Revenue (1Y)10.74%
Earnings (1Y)-483.50%
FCF Growth (3Y)108.26%
الجودة
Return on Equity
-19.24%
ROIC8.94%
Net Margin-17.47%
Op. Margin14.36%
الأمان
Debt / Equity
0.39
Current Ratio1.36
Interest Coverage4.04
التقييم
P/E Ratio
-14.07
P/B Ratio2.84
EV/EBITDA16.30
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 10.74% | Revenue Growth (3Y) | 9.70% |
| Earnings Growth (1Y) | -483.50% | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 7.60% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 1.39B | Net Income (TTM) | -242.50M |
| ROE | -19.24% | ROA | -9.31% |
| Gross Margin | 67.71% | Operating Margin | 14.36% |
| Net Margin | -17.47% | Free Cash Flow (TTM) | 173.20M |
| ROIC | 8.94% | FCF Growth (3Y) | 108.26% |
| Safety | |||
| Debt / Equity | 0.39 | Current Ratio | 1.36 |
| Interest Coverage | 4.04 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | -14.07 | P/B Ratio | 2.84 |
| P/S Ratio | 2.46 | PEG Ratio | 0.03 |
| EV/EBITDA | 16.30 | Dividend Yield | 0.00% |
| Market Cap | 3.41B | Enterprise Value | 3.25B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.39B | 1.25B | 1.15B | 1.02B | 1.04B |
| Net Income | -242.50M | 63.23M | 17.55M | -86.25M | -135.82M |
| EPS (Diluted) | -4.45 | 1.16 | 0.32 | -1.61 | -2.68 |
| Gross Profit | 939.90M | 870.87M | 771.25M | 707.23M | 705.99M |
| Operating Income | 199.40M | 129.05M | -68.50M | -76.75M | -784,000.0 |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 2.61B | 2.51B | 2.43B | 2.29B | 2.20B |
| Total Liabilities | 1.41B | 1.19B | 1.15B | 1.09B | 906.31M |
| Shareholders' Equity | 1.20B | 1.32B | 1.28B | 1.21B | 1.29B |
| Total Debt | 473.30M | 676.77M | 640.40M | 580.43M | 286.70M |
| Cash & Equivalents | 635.60M | 428.86M | 266.50M | 214.17M | 207.99M |
| Current Assets | 1.10B | 1.13B | 988.16M | 886.14M | 679.18M |
| Current Liabilities | 808.10M | 392.13M | 334.98M | 297.40M | 696.97M |